source
- Epicrispr raises $90 million to push epigenetic editing drug EPI-321 for rare muscle disorder FSHDEpicrispr Biotechnologies announced a $90 million Series C financing to accelerate development of its epigenetic editing therapy EPI-321 for facioscapulohumeral muscular dystrophy (FSHD), a rare ge…
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczemaInfinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.BioPharma Dive · 1h ago↗ source